Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity [TheStreet.com]
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript [Seeking Alpha]
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference